Latest revenue
$21.1M
as of 2026-03-31
Latest net income
$127.1M
as of 2026-03-31
Net margin
600.9%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $401.8M
- Enterprise value
- $401.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $1.72
- 52-wk low
- $0.87
- Beta
- —
- Shares out
- 390.1M
5-year trend
What this company does
ITEM 1. BUSINESS Overview At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological…
AI summary unavailable — showing raw filing excerpt
Generated from LAB's filing dated 2026-03-16
Key risks
ITEM 1A. RISK FACTORS We operate in a rapidly changing environment that involves numerous uncertainties and risks. The following risks and uncertainties may have a material and adverse effect on our business, financial condition, or results of operations. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this Annual Report. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, global sociopolitical events and international operations. Further, additional risks…
AI summary unavailable — showing raw filing excerpt
Generated from LAB's filing dated 2026-03-16
Profitability
Gross margin
49.9%
3.2%Operating margin
-129.2%
28.6%Net margin
-87.8%
10.2%Return on equity
-17.7%
40.0%Return on assets
-13.2%
41.8%Leverage
Debt / equity
0.34×
13.4%Long-term debt / equity
0.00×
100.0%Debt / assets
25.3%
10.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $21.1M | +4.6% | $127.1M | +588.1% | 600.9% |
Q4 2025 2025-12-31 | $23.8M | -71.8% | $19.3M | +156.6% | 81.0% |
Q3 2025 2025-09-30 | $19.6M | -11.5% | $-34.7M | -28.8% | -177.4% |
Q2 2025 2025-06-30 | $21.8M | -3.2% | $-33.5M | +26.8% | -153.7% |
Q1 2025 2025-03-31 | $20.2M | -55.6% | $-26.0M | +19.0% | -128.7% |
Q4 2024 2024-12-31 | $84.3M | — | $-34.1M | — | -40.4% |
Q3 2024 2024-09-30 | $22.1M | -12.9% | $-26.9M | -28.3% | -122.0% |
Q2 2024 2024-06-30 | $22.5M | -18.7% | $-45.7M | -168.3% | -203.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on LAB — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$16.3M
Insider selling
$0
Net activity
+$16.3M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns LAB
Institutional value
$55.9M
Total shares held
61.2M
Distinct holders
85
-73 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 24.8M | $22.8M | -759.8K (-3.0%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 12.8M | $11.8M | — | New |
| 3 | Hollow Brook Wealth Management LLC | 5.7M | $5.2M | +100.0K (+1.8%) | Added |
| 4 | ROYCE & ASSOCIATES LP | 3.0M | $2.8M | +120.0K (+4.2%) | Added |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $2.2M | — | New |
| 6 | Peapod Lane Capital LLC | 2.0M | $1.9M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 1.9M | $1.8M | — | New |
| 8 | Bank of New York Mellon Corp | 767.0K | $705.1K | -26.6K (-3.4%) | Trimmed |
| 9 | Nuveen, LLC | 661.2K | $607.8K | +4.0K (+0.6%) | Added |
| 10 | STALEY CAPITAL ADVISERS INC | 632.4K | $581.4K | — | New |
| 11 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 519.8K | $477.7K | +0 (+0.0%) | No change |
| 12 | Swiss National Bank | 489.7K | $450.1K | +0 (+0.0%) | No change |
| 13 | Nikko Asset Management Americas, Inc. | 442.8K | $407.4K | -3.9M (-89.8%) | Trimmed |
| 14 | Sumitomo Mitsui Trust Group, Inc. | 442.8K | $407.1K | -3.9M (-89.8%) | Trimmed |
| 15 | Intellectus Partners, LLC | 404.7K | $372.0K | +0 (+0.0%) | No change |
| 16 | RHUMBLINE ADVISERS | 364.9K | $335.3K | -9.6K (-2.6%) | Trimmed |
| 17 | OPPENHEIMER & CO INC | 350.9K | $322.6K | +231.1K (+193.0%) | Added |
| 18 | JOHNSON & JOHNSON | 312.0K | $286.8K | -312.0K (-50.0%) | Trimmed |
| 19 | UBS Group AG | 305.1K | $280.4K | +40.7K (+15.4%) | Added |
| 20 | DEUTSCHE BANK AG\ | 285.8K | $262.9K | +29.9K (+11.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once LAB's latest filing finishes processing.